NDLI: Predictors of continuation for asenapine from real-world data in patients with schizophrenia

Content Provider	Springer Nature : BioMed Central
Author	Takekita, Yoshiteru Hiraoka, Shuichi Iwama, Yasuhiro Matsui, Daisuke Aoki, Nobuatsu Ogata, Haruhiko Funatsuki, Toshiya Shimizu, Toshiyuki Murase, Yuji Shimamoto, Yutaro Koshikawa, Yosuke Kato, Masaki
Abstract	Background The continuation rates of pharmacotherapy in schizophrenia exhibit variability, a phenomenon influenced by the specific antipsychotic agent prescribed and patient-related factors such as age and duration of illness. In this context, our study aims to elucidate the predictors of medication continuation for asenapine sublingual tablets, characterized by unique formulation properties. Methods Our investigation leveraged real-world data collected through post-marketing surveillance in Japan, comprising 3236 cases. Utilizing multivariate logistic regression analysis, we identified patient-related factors associated with medication continuation as the primary outcome measure, subsequently employing survival analysis for further evaluation. Additionally, adverse event occurrence was assessed as a secondary outcome measure. Results Multivariate logistic regression analysis unveiled significant predictors of asenapine continuation, notably including patient-related factors such as a chlorpromazine equivalent dose exceeding 600 mg/day and an illness duration of 25 years or more. While the overall continuation rate stood at 40.6%, patients exhibiting factors such as a chlorpromazine equivalent dose surpassing 600 mg/day or an illness duration exceeding 25 years demonstrated continuation rates of 46.3% and 47.9%, respectively. Remarkably, patients presenting both factors showcased the highest continuation rate at 52.5%. Conclusions Our findings shed light on distinct patient-related predictors of asenapine continuation, deviating from those observed with other antipsychotic medications. This underscores the necessity of recognizing that predictive factors for antipsychotic medication continuation vary across different agents. Moving forward, elucidating these predictive factors for various antipsychotic medications holds paramount importance in schizophrenia treatment, facilitating the delivery of tailored therapeutic interventions for individual patients.
Related Links	https://annals-general-psychiatry.biomedcentral.com/counter/pdf/10.1186/s12991-024-00512-2.pdf
Ending Page	8
Page Count	8
Starting Page	1
File Format	HTM / HTML
DOI	10.1186/s12991-024-00512-2
Journal	Annals of General Psychiatry
Issue Number	1
Volume Number	23
Language	English
Publisher	BioMed Central
Publisher Date	2024-08-02
Access Restriction	Open
Subject Keyword	Psychiatry Psychopharmacology Forensic Psychiatry Geriatric Psychiatry Psychotherapy Schizophrenia Predictor Asenapine Continuation rate Real world data
Content Type	Text
Resource Type	Article
Subject	Psychiatry and Mental Health
Journal Impact Factor	3.6/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Real-world predictors of divorce among outpatients with bipolar disorder: sex differences and clinical implications

Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia

Continuation with clozapine after eosinophilia: a case report

Antipsychotic therapy: from meta-analysis experience to real-world clinical practice

Rapid control of agitation in patients with schizophrenia

Challenge in rehabilitation in patients with schizophrenia

Predictors of antipsychotics switching among ambulatory patients with schizophrenia in Ethiopia: a multicenter hospital-based cross-sectional study

Body composition in patients with schizophrenia: Comparison with healthy controls

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Predictors of continuation for asenapine from real-world data in patients with schizophrenia

Similar Documents

Real-world predictors of divorce among outpatients with bipolar disorder: sex differences and clinical implications

Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia

Continuation with clozapine after eosinophilia: a case report

Antipsychotic therapy: from meta-analysis experience to real-world clinical practice

Rapid control of agitation in patients with schizophrenia

Challenge in rehabilitation in patients with schizophrenia

Predictors of antipsychotics switching among ambulatory patients with schizophrenia in Ethiopia: a multicenter hospital-based cross-sectional study

Body composition in patients with schizophrenia: Comparison with healthy controls

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Predictors of continuation for asenapine from real-world data in patients with schizophrenia